91AV

Introduction

Despite major efforts to tackle cancer, it is still a leading cause of death worldwide that places tremendous health and economic burden on societies. Given this, developing new approaches to attack tumours continues to be a key area of research for both academia and industry. The recent emergence of rationally designed targeted drugs and effective immunotherapies, based on a deeper understanding of cancer genomics and the host/tumour interaction, has allowed significant progress to be made even in those indications that have historically been hard to treat. This SMR symposium, in collaboration with Cancer Research UK, brings together a panel of international speakers to highlight exciting new advances in cancer therapy, and to discuss key challenges and opportunities from early research through to clinical development

Deadlines

• Jun 02 2015
  Standard registration deadline

  

Useful links

Speakers

• Herbie Newell Newcastle University, United Kingdom
• Martin Drysdale CR-UK Beatson Institute, Glasgow, United Kingdom
• Juan-Miguel Jimenez Vertex, United Kingdom
• Robert Wilkinson MedImmune, United Kingdom
• Charles Swanton CR-UK London Research Institute, United Kingdom
• Dr Karthik Venkatakrishnan Takeda, United States
• Dr Philipp Holzer, Novartis Basel, Switzerland
• Namir Hassan Immunocore, United Kingdom
• Hazel Jones and Glenn Clack Joint presentation by CRUK Centre for Drug Development & AstraZeneca, United Kingdom

---

Sponsorship & supporting organisations

CR-UK Beatson Institute

Venue

CR-UK Beatson Institute

CR-UK Beatson Institute, Switchback Road, Glasgow, Bearsden, Glasgow City , G61 1BD, United Kingdom

Useful links

Organised by

Society of Medicines research

Contact information

Stuart Hex
Society of Medicines Research
Q House
Troon Way Business Centre
Humberstone Lane
Thurmaston
Leicester
LE4 9HA
+44 (0)116 274 7356
Contact us by email

---